What is the recommended approach for managing a patient on Suboxone (buprenorphine‑naloxone) during referral to a nursing‑home, including dosing, monitoring, and follow‑up?

Suboxone Management During Nursing Home Referral

Continue the patient's current Suboxone dose without interruption during nursing home transfer, ensuring the receiving facility has prescribing capability and monitoring protocols in place before admission. 1

Key Management Principles

Medication Continuity

• Maintain the established maintenance dose (typically 12-24 mg/day) without taper or interruption during transfer 2
• The FDA-approved target maintenance dose is 16 mg/day, though doses from 12-24 mg are clinically effective 2
• Abrupt discontinuation risks precipitating withdrawal and return to illicit opioid use, significantly increasing mortality risk 2

Pre-Transfer Coordination

Essential steps before nursing home admission:

• Verify prescribing capability: Confirm the nursing home has a clinician with DEA-controlled substance license who can prescribe buprenorphine (no waiver required as of current regulations) 3

• Establish monitoring protocols: Ensure nursing staff understand sublingual administration technique and can monitor for:

  • Signs of withdrawal (Clinical Opiate Withdrawal Scale monitoring)
  • Respiratory depression, particularly if patient receives other CNS depressants 2
  • Drug interactions, especially QT-prolonging agents (contraindicated with buprenorphine) 1

• Document indication: Clarify whether Suboxone is prescribed for opioid use disorder versus chronic pain management, as this affects monitoring intensity 1

Administration Protocol for Nursing Home Staff

Critical administration details:

• Sublingual placement only: Tablets must dissolve completely under the tongue; swallowing reduces bioavailability 2
• Single daily dosing: Administer as one daily dose (not divided) 2
• Multiple tablet technique: If dose requires >2 tablets, either place all simultaneously or 2 at a time until complete dose administered 2
• Consistency matters: Use the same administration method daily to maintain stable bioavailability 2

Monitoring Requirements

Nursing home staff should monitor for:

• Respiratory depression risk factors: Particularly dangerous with concomitant benzodiazepines, alcohol, or other CNS depressants—multiple deaths reported with this combination 2
• Hepatic function: Baseline and periodic liver function tests recommended, as buprenorphine associated with hepatotoxicity risk (though often confounded by hepatitis B/C, other hepatotoxic drugs, or ongoing substance use) 2
• Withdrawal symptoms: Inadequate dosing manifests as opioid withdrawal (not simply "pain")
• Allergic reactions: Rash, hives, pruritus, or rarely bronchospasm/angioedema 2

Critical Safety Warnings

Absolute contraindications and precautions:

• Avoid benzodiazepines: Concomitant use significantly increases respiratory depression and death risk 2
• QT-prolonging agents contraindicated: Do not combine with medications that prolong QT interval 1
• Naloxone ineffective for overdose: Standard naloxone may not reverse buprenorphine-induced respiratory depression; mechanical ventilation is primary management 2
• Compromised respiratory function: Use extreme caution in COPD, cor pulmonale, or pre-existing respiratory depression 2

Common Pitfalls to Avoid

1. Do not taper or discontinue during transfer "for simplicity"—this dramatically increases relapse and mortality risk
2. Do not assume nursing homes can prescribe—verify prescribing capability before admission to prevent treatment interruption
3. Do not allow oral swallowing—this is the most common administration error reducing efficacy
4. Do not combine with benzodiazepines without extreme caution and respiratory monitoring
5. Do not treat breakthrough pain with full opioid agonists without understanding buprenorphine's partial agonist properties may require higher-than-normal opioid doses 4

Pain Management Considerations

If patient requires acute pain management while on Suboxone:

• Continue buprenorphine for doses ≤12 mg/day 1
• For higher doses: Consider tapering to 12 mg over 2-3 days before procedures if significant post-procedure pain expected 1
• Multimodal analgesia: NSAIDs, acetaminophen, regional techniques, and local anesthetics are cornerstone 4
• Full agonist opioids: Can be added if needed, but expect requirement for higher-than-normal doses due to buprenorphine's high mu-receptor affinity 4, 1

Follow-Up Structure

• Prescriber continuity: Establish which clinician (nursing home physician vs. original prescriber) will manage ongoing Suboxone therapy
• Frequency: Weekly initially, then monthly once stable 2
• Urine drug testing: Periodic monitoring appropriate for opioid use disorder indication 5
• Dose optimization: Adjust in 2-4 mg increments based on withdrawal symptoms, craving, and illicit use 2, 6